GATA-3 as a Potential Therapeutic Target for Insulin Resistance and Type 2 Diabetes Mellitus

Author(s): Hend Al-Jaber, Layla Al-Mansoori, Mohamed A. Elrayess*

Journal Name: Current Diabetes Reviews

Volume 17 , Issue 2 , 2021

Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Impaired adipogenesis plays an important role in the development of obesityassociated insulin resistance and type 2 diabetes as it leads to ectopic fat deposition.

The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets responsible for the impairment of adipogenesis. The expression of GATA-3 is higher in insulinresistant obese individuals compared to BMI-matched insulin-sensitive counterparts. Adipose tissue inflammation is a crucial mediator of this process.

Hyperglycemia mediates the activation of the immune system, partially through upregulation of GATA- 3, causing exacerbation of the inflammatory state associated with obesity.

This review discusses the evidence supporting the inhibition of GATA-3 as a useful therapeutic strategy in obesity-associated insulin resistance and type 2 diabetes, through up-regulation adipogenesis and amelioration of the immune response.

Keywords: GATA-3, therapeutic target, insulin resistance, adipogenesis, inflammation, type 2 diabetes.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2021
Page: [169 - 179]
Pages: 11
DOI: 10.2174/1573399816666200705210417
Price: $95

Article Metrics

PDF: 4